|
2025 Journal Article Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosisChakraborty, Rajshekhar, Kastritis, Efstathios, Huart, Antoine, Jaccard, Arnaud, Landau, Heather, Iida, Shinsuke, Motorna, Olga, Mollee, Peter, Ishida, Tadao, Kawano, Yawara, Bhutani, Manisha, D'Souza, Anita, Cowan, Andrew, Hoffman, James, Talati, Chetasi, Rosenberg, Tanya, La Motte-Mohs, Ross, Wang, Fan, Hoffman, David, Fei, Mingwei, Arriola, Emma, Yu, Jovian, Kumar, Shaji, Dispenzieri, Angela, Palladini, Giovanni and Sanchorawala, Vaishali (2025). Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis. Blood, 146 (Supplement 1), 692-692. doi: 10.1182/blood-2025-692 |
|
2025 Journal Article Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)Rees, Matthew, Lasica, Masa, Kalff, Anna, Low, Michael, Harrup, Rosemary, Lai, Hock Choong, Sidiqi, M Hasib, Wong Doo, Nicole, Routledge, David, Hocking, Jay, Campbell, Philip, Heenan, Jessica, Horvath, Noemi, Chien, Nicole, Renwick, William, McCaughan, Georgia, Eek, Richard, Lenton, Douglas, Gazdar, Sher Gul, Mazumdar, Deepmala, Butcher, Belinda, Mollee, Peter and Quach, Hang (2025). Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND). Blood, 146 (Supplement 1), 4039-4039. doi: 10.1182/blood-2025-4039 |
|
2025 Journal Article Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groupsZammar, Ghassan, Augustson, Bradley, Moore, Elizabeth, Sidiqi, M Hasib, Wellard, Cameron, Ashrafi, Elham, Harrison, Simon, Radeski, Dejan, Jackson, Alannah, Bergin, Krystal, Ho, Phoebe Joy, King, Tracy, Mollee, Peter, Quach, Hang, Rajagopal, Rajeev, McQuilten, Zoe, Wood, Erica, Rosengarten, Brian and Spencer, Andrew (2025). Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups. Blood, 146 (Supplement 1), 2221-2221. doi: 10.1182/blood-2025-2221 |
|
2025 Journal Article Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)Lim, Sueh-Li, Reynolds, John, Pemberton, Lucy, Wright, Tricia, Lee, Sophie, Mollee, Peter, Shetty, Anita C., Kim, Yu Jin, Helen, Weston, Nina, Byard, Le, Khoa, McQuilten, Zoe, Quach, Hang and Spencer, Andrew (2025). Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22). Blood, 146 (Supplement 1), 5842-5842. doi: 10.1182/blood-2025-5842 |
|
2025 Journal Article A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of AmyloidosisSanchorawala, Vaishali, Wechalekar, Ashutosh, Mollee, Peter, Sekijima, Yoshiki, Maurer, Mathew S., Leung, Nelson, Schönland, Stefan O. and Kumar, Shaji (2025). A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis. Amyloid, 32 (4), 1-6. doi: 10.1080/13506129.2025.2570096 |
|
2025 Conference Publication Identification of Extracardiac Organ Involvement in Systemic Light Chain Amyloidosis using 18F-Florbetaben Positron Emission TomographyAnderson, Nirija Ranjit, Law, Phillip, Harrop, Danielle, Ng, Arnold, Wang, William, Korczyk, Dariusz and Mollee, Peter (2025). Identification of Extracardiac Organ Involvement in Systemic Light Chain Amyloidosis using 18F-Florbetaben Positron Emission Tomography. International Myeloma Society 22nd Annual Meeting and Exposition, Toronto, Canada, 17-20 September 2025. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(25)03616-x |
|
2025 Conference Publication A Randomized Controlled Trial of Bone-Targeted Exercise for People with Multiple Myeloma: The MyeEx-Impact StudyNicol, Jennifer, King, Tracy, Chong, Jamie, Cunningham, Brent, Hart, Nicolas, Kay, Shelley, Woodrow, Carmel, Beck, Belinda, McDonald, Michelle, Carter, Daniel, Beer, Hayley, Boytar, Alex, Baguley, Brenton, Farley, Morgan, Rose, Grace, Mollee, Peter and Skinner, Tina (2025). A Randomized Controlled Trial of Bone-Targeted Exercise for People with Multiple Myeloma: The MyeEx-Impact Study. International Myeloma Society 22nd Annual Meeting and Exposition, Toronto, Canada, 17-20 September 2025. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(25)03992-8 |
|
2025 Conference Publication Early Venetoclax Salvage in Systemic Light Chain Amyloidosis: A Retrospective Case SeriesMcVilly, Nicholas, Mollee, Peter, Anderson, Nirija Ranjit, Rowland, James, Korczyk, Dariusz, Sheikh, Nabeel and Abro, Emad (2025). Early Venetoclax Salvage in Systemic Light Chain Amyloidosis: A Retrospective Case Series. International Myeloma Society 22nd Annual Meeting and Exposition, Toronto, Canada, 17-20 September 2025. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(25)03824-8 |
|
2025 Conference Publication Outcomes of Patients with Multiple Myeloma Post-BCMA Directed Treatment: An Australian PerspectiveLing, Jessica, Moore, Elizabeth, Wellard, Cameron, Spencer, Andrew, Ho, P. Joy, Mollee, Peter, Harrison, Simon, Augustson, Bradley, Quach, Hang and Sidiqi, M. Hasib (2025). Outcomes of Patients with Multiple Myeloma Post-BCMA Directed Treatment: An Australian Perspective. International Myeloma Society 22nd Annual Meeting and Exposition, Toronto, Canada, 17-20 September 2025. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(25)03520-7 |
|
2025 Journal Article Visualizing amyloidosis: The role of radionuclide imaging in systemic amyloidosisRanjit Anderson, Nirija, Dorbala, Sharmila and Mollee, Peter (2025). Visualizing amyloidosis: The role of radionuclide imaging in systemic amyloidosis. Blood Journal, 146 (10) blood.2024026386, 1157-1162. doi: 10.1182/blood.2024026386 |
|
2025 Journal Article Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomesPerrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Wang, George, Gupta-Werner, Niodita, Kaila, Shuchita, Pei, Huiling, Matt, Kathryn, Gries, Katharine S., Carson, Robin, Borgsten, Fredrik and Weisel, Katja (2025). Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes. European Journal of Haematology, 114 (5), 883-889. doi: 10.1111/ejh.14392 |
|
2025 Journal Article Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma patientsLim, Kenneth J C, Wellard, Cameron, Moore, Elizabeth, Ninkovic, Slavisa, Chng, Wee Joo, Spencer, Andrew, Mollee, Peter, Hocking, Jay, Ho, P. Joy, Janowski, Wojt, Kim, Kihyun, McCaughan, Georgia, Dun, Karen, McQuilten, Zoe, Chen, Fiona and Quach, Hang (2025). Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma patients. Clinical Lymphoma Myeloma and Leukemia, 25 (4), 243-248. doi: 10.1016/j.clml.2024.11.002 |
|
2025 Journal Article Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: a systematic reviewSia, Aaron, Chopra, Sakshi, Ling, Victoria Y., Fletcher, James, Hubbard, Ruth Eleanor, Mollee, Peter, Gordon, Emily, Reid, Natasha and Hanjani, Leila Shafiee (2025). Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: a systematic review. Journal of Geriatric Oncology, 16 (3) 102196, 102196. doi: 10.1016/j.jgo.2025.102196 |
|
2025 Journal Article Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomised controlled trialHapgood, Greg, Hill, Kate, Okano, Satomi, Abro, Emad, Looke, David, Kennedy, Glen, Pavilion, Gilbert, Van Kuilenburg, Rosita, Geary, Alanna, Joubert, Warren, Eastgate, Melissa, Jones, Mark and Mollee, Peter (2025). Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomised controlled trial. Journal of Thrombosis and Haemostasis, 23 (2), 627-634. doi: 10.1016/j.jtha.2024.11.002 |
|
2025 Conference Publication Amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometryMollee, Peter (2025). Amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry. Pathology Update 2025, Melbourne, VIC Australia, 21-23 February 2025. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.pathol.2024.12.033 |
|
2025 Journal Article A Comparison of Peripherally Inserted Central Catheter MaterialsUllman, Amanda J., August, Deanne, Kleidon, Tricia M., Walker, Rachel M., Marsh, Nicole, Bulmer, Andrew C., Pearch, Ben, Runnegar, Naomi, Leema, Joanne, Lee-Archer, Paul, Biles, Cathy, Gibson, Victoria, Royle, Ruth, Southam, Katrina, Byrnes, Joshua, Chopra, Vineet, Coulthard, Alan, Mollee, Peter, Rickard, Claire M., Harris, Patrick N. A. and Ware, Robert S. (2025). A Comparison of Peripherally Inserted Central Catheter Materials. New England Journal of Medicine, 392 (2), 161-172. doi: 10.1056/nejmoa2406815 |
|
2024 Conference Publication Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases RegistryLim, Kenneth J. C., Wellard, Cameron, Moore, Elizabeth, Gration, Betty, Augustson, Bradley, Mollee, Peter, Zhang, Jennifer, Wong Doo, Nicole, Ringkowski, Sabine, Bryant, Adam, Ninkovic, Slavisa, Hamad, Nada, McCaughan, Georgia, Kumar, Shaji, Spencer, Andrew and Quach, Hang (2024). Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-207609 |
|
2024 Conference Publication Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)Gration, Betty, Wellard, Cameron, Moore, Elizabeth, Mollee, Peter, Kerridge, Ian H., Spencer, Andrew, Shetty, Anita, Baker, Bart, Forsyth, Cecily, Heenan, Jessica, McQuilten, Zoe K, Wood, Erica M. and McCaughan, Georgia (2024). Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR). 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-199451 |
|
2024 Conference Publication Plasma Cell Enumeration By Manual and Automated Methods to Establish a Standard Pictorial ReferenceMurali, Aarya, Tobin, Joshua W.D. and Mollee, Peter (2024). Plasma Cell Enumeration By Manual and Automated Methods to Establish a Standard Pictorial Reference. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204199 |
|
2024 Conference Publication Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLGMollee, Peter, Huart, Antoine, Mortona, Olga, Queru, Kentin, Leyronnas, Cecile, Stephanie, Harel, Sidiqi, Hasib, Desport, Estelle, Vincent, Laure, Macro, Margaret, Manier, Salomon, Jacquet, Caroline, Morel, Pierre, Horvath, Noemi, Bender, Sebastien, Olombel, Guillaume, Pascal, Virginie, Corre, Jill, Bridoux, Frank, Jaccard, Arnaud and Roussel, Murielle (2024). Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204700 |
